InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (2 ops.)
Insider track record
CEODisclosed buys
1
Disclosed sells
2
T+90 hit rate
67%
T+90 mean return
+8.8%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by McMinn Rachel, Chief Executive Officer. Officer active across 2 companies, notably Neurogene Inc.. In total, 7 reports have been logged. Breakdown: 1 buy · 2 sells. Total volume traded: €926k. Activity tracked since 22 November 2024. The latest transaction was filed on 20 February 2026 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Declarations7 total
25,900 shares0Common StockSEC:0001606302-26-000002:0
25,900 shares0Common StockSEC:0001606302-26-000002
23,900 shares0Common StockSEC:0001404644-25-000020:0
47,500 shares@ US$20.40100.0% of flowCommon StockSEC:0001404644-24-000112:0
Ideal exit: 19 Aug 2025 (T+270)
6,700 sharesCommon StockSEC:0001144204-16-081815:0
128 sharesCommon StockSEC:0001144204-16-078888:0
469 sharesCommon StockSEC:0001144204-16-074240:0
7 of 7 declarations
About McMinn Rachel
Rachel McMinn is the Chief Executive Officer of Neurogene Inc. She leads the company, focusing on growth strategy and innovation. Her leadership is crucial for achieving organizational goals and strengthening the market position of the firm.
